AXSM Axsome Therapeutics Inc.

2.70
+0.10  (4%)
Previous Close 2.60
Open 2.60
Price To book 4.09
Market Cap 68728198
Shares 25,454,888
Volume 328,114
Short Ratio 1.22
Av. Daily Volume 489,860

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial to be initiated 1Q 2018.
AXS-05
Smoking cessation
Phase 2/3 initiation announced July 17, 2017.
AXS-05 ADVANCE-1
Agitation in patients with Alzheimer’s disease (AD)
Phase 3 interim efficacy analysis January 9, 2017 recommended trial to discontinue due to futility.
AXS-02 CREATE-1
Complex regional pain syndrome (CRPS)
Phase 3 initiated March 2016. Top-line data due 1H 2018.
AXS-05 STRIDE-1
Treatment resistant depression
Phase 3 interim efficacy analysis January 9, 2017 recommended trial continue to full enrollment.
AXS-02 COAST-1
Knee Osteoarthritis Associated with Bone Marrow Lesions
Phase 3 initiation contingent upon resources.
AXS-02
Chronic Low Back Pain Associated with Modic Changes